Red Light Holland (TRIP) Q4 2026 earnings summary

Executive summary

• Completed acquisition of Filament Health, expanding pharmaceutical manufacturing, regulatory, and clinical research capabilities, including naturally derived psilocybin development and the PEX010 drug candidate.

• Rebranding to Rhelion Life Sciences Corp. effective August 4, 2026, reflecting a shift to a science-first, life sciences focus.

• Fiscal 2026 focused on simplifying legacy businesses, exiting non-core operations, and building a vertically integrated psychedelic drug platform.

• Expanded international research network and supply agreements, supporting over 80 clinical studies worldwide.

Financial highlights

• Total cash balance decreased to $8.471M in 2026 from $12.838M in 2025.

• Revenue declined to $4.195M in 2026 from $4.944M in 2025, a 15.15% decrease.

• Gross profit fell to $1.591M in 2026 from $1.913M in 2025, down 16.84%.

• EBITDA loss increased to $6.754M in 2026 from $3.354M in 2025; adjusted EBITDA loss rose to $2.931M from $2.532M.

• Total assets dropped to $14.570M as of March 31, 2026, from $21.221M a year earlier.

Outlook and guidance

• Focus for fiscal 2027 is on advancing naturally derived drug development, expanding licensing and supply opportunities, and leveraging intellectual property.

• Plans to advance PEX010 and other candidates into later-stage clinical development, including a potential Phase 2b trial.

• Continued disciplined capital allocation and evaluation of strategic acquisitions and partnerships.

• Ongoing optimization and potential monetization of non-core assets.